This work has since progressed to a phase 1b clinical trial, where near-complete clinical responses were observed in one of six patients with non-small cell lung cancer (NSCLC) using dupilumab (anti–IL-4Rα) in combination with PD-1/PD-L1 checkpoint inhibitors (38). This evidence concerns the gene IL4R and non-small cell lung carcinoma.